Our risk management procedures allow us to minimize the fund’s drawdown during difficult timesback to investment strategy
The portfolio is structured in such a way that the maximum loss from one position should not be higher than 3% of the total assets in the portfolio.
The weight of a biotech company, where the drugs are at the 1st or 2nd stage of clinical studies, should not exceed 5% in the portfolio.
We follow UCITS diversification principles with maximum allocation to one position of 10%. But we do not follow UCITS portfolio concentration principles, as making focused, concentrated bets is part of our strategy. The weight of the top 10 holdings can be up to 60% of the portfolio.